Scientific Online Resource System

Scripta Scientifica Medica

Significant inhibition of the triggering mechanism of the extrinsic system of blood coagulation in rats by thymus peptides thymulin, thymosin alpha 1 and thymosin beta 4

Yuri Nyagolov, Kiril Hristozov, Antoniya Hachmeryan

Abstract

INTRODUCTION: The role of the thymus gland and the effects of thymic peptides on the coagulation status are relatively insufficiently studied. Recent data indicate controversial and not persuasive results due to in­vestigation of single hemostasis parameters and application of various pathological models.

AIM: The present study aimed to elucidate the influence of thymus peptides thymulin, thymosin alpha 1 and thymosin beta 4 applied s.c. on intact rats, on key triggering factors of blood coagulation via the extrin­sic pathway: plasma concentration of tissue factor (TF); concentration and activity of free TFPI; and the ac­tivity of plasma clotting factor VII, as well as on prothrombin time (PT) - an integral clinical parameter of the intrinsic pathway.

MATERIALS AND METHODS: The study was performed on 52 male Wistar strain rats, weighing 200-220 g and bred under standard conditions at dark/light cycle 12/12 h. The rats were divided into four equal groups (n=13) and injected s.c. once daily in the time interval 08.00-09.00 h in the course of three consecutive days as follows: 1st group (controls) - with saline (the solvent of the peptides); 2nd group - with thymulin (Sigma Aldrich, 0.4 mg/kg b.m.); 3rd group - with thymosin alpha 1 (Sigma Aldrich, 0.3 mg/kg b.m.); and the 4th group - with thymosin beta 4 (Sigma Aldrich, 0.3 mg/kg b.m.).

RESULTS: Results indicate that thymulin and thymosin alpha 1 expressively decrease TF and increase TFPI concentrations. All three thymic peptides reduce FVIIa activity, increase TFPI activity, and significantly elongate PT.

CONCLUSIONS: Thymus peptides thymulin, thymosin alpha 1 and thymosin beta 4 significantly suppress blood coagulation through the extrinsic pathway and generate a distinct tendency for hypocoagulability.


Keywords

: thymulin, thymosin alpha 1, thymosin beta 4, TF, FVII, TFPI, PT

Full Text


References

Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58 (5):515-23. doi: 10.4103/0019-5049.144643

Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol. 2004;79(2):103-8. doi: 10.1532/IJH97.03167

Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24(6):1015-1022. doi: 10.1161/01.ATV.0000130465.23430.74

Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Thromb Haemost. 1997;78(1):401-5.

Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108(5):1447-52. doi: 10.1213/ ane.0b013e31819bceb1

Gajsiewicz JM, Morrissey JH. Structure-Function Relationship of the Interaction between Tissue Factor and Factor VIIa. Semin Thromb Hemost. 2015;41(7):682-90. doi: 10.1055/s-0035-1564044

Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factor VII. Thromb Haemost. 2005;94(3):493-7. doi: 10.1160/TH05-05-0337

Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost. 2015;13(1):200-7. doi: 10.1111/jth.12897

Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth. 2006;53 (Suppl 2):2-11. doi:10.1007/BF03022247

Mast AE. Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. Arterioscler Thromb Vasc Biol. 2016;36(1):9-14. doi: 10.1161/ATVBAHA.115.305996

Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A. 2013;110(44):17838-43. doi: 10.1073/ pnas.1310444110

Franchini M, Lippi G, Manzato F, Vescovi P, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol. 2010;162(3):439-51. doi: 10.1530/EJE-09-0958

Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82(2):165-174.

Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost 1999;25(4):407-418. doi: 10.1055/s-2007-994943

Genecov DG, Por YC, Barcelo CR, Salyer KE, Mulne AF, Morad AB. Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling. Plast Reconstr Surg. 2005;116(2):389-94. doi: 10.1097/01. prs.0000172760.79803.68

Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J. 2003;4(6):373- 8. doi: 10.1038/sj.thj.6200306

Franchini M, Vescovi PP, Manzato F, Favaloro EJ. Hormones, endocrine disorders, and hemostasis. Semin Thromb Hemost. 2011;37(1):3-5. doi: 10.1055/s-0030-1270064

Liapina LA, Pastorova VE, Kudriashov BA, ZazhireÄ­ VD, Sokolova EA, Lishvits VA et al. The action of timoptin peptides on the hemostatic system. Izv Akad Nauk SSSR Biol. 1990;3:377-82.

Andreenko GV, Ashmarin IP, ZazhireÄ­ VD, Livshits VA, Serebriakova TN, Podorol`skaia LV. The effect of thymoptin on enzymatic fibrinolysis. Vopr Med Khim. 1989;35(5):108-11.

Ellery PE, Adams MJ. Tissue factor pathway inhibitor: then and now. Semin Thromb Hemost. 2014;40(8):881-6. doi: 10.1055/s-0034-1395153

Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-54. doi: 10.1111/jth.12864




DOI: http://dx.doi.org/10.14748/ssm.v49i2.3391

Refbacks

About The Authors

Yuri Nyagolov
Medical University Sofia, Department Physiology
Bulgaria

Kiril Hristozov
Medical University of Varna department of endicrinology
Bulgaria

Antoniya Hachmeryan
Medical University of Varna, department of Physiology
Bulgaria

Font Size


|